Stifel analyst Thomas Shrader weighed in on Esperion Therapeutics (NASDAQ: ESPR) after the company released data from the 035 study to test ETC-1002 on top of low dose statins. He said the complex will likely leave both bulls and bears happy. He also used the updated as chance to lower his price target to $30 from $64. He maintained a Buy... More